PTC Therapeutics, Inc. Stock

Equities

PTCT

US69366J2006

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:26:30 2024-06-13 pm EDT 5-day change 1st Jan Change
36.9 USD -2.06% Intraday chart for PTC Therapeutics, Inc. -0.38% +33.49%
Sales 2024 * 760M Sales 2025 * 844M Capitalization 2.89B
Net income 2024 * -385M Net income 2025 * -187M EV / Sales 2024 * 3.14 x
Net cash position 2024 * 503M Net cash position 2025 * 424M EV / Sales 2025 * 2.92 x
P/E ratio 2024 *
-7.49 x
P/E ratio 2025 *
-14.2 x
Employees 1,022
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.58%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.05%
1 week-0.87%
Current month+3.60%
1 month+16.81%
3 months+18.87%
6 months+44.27%
Current year+36.68%
More quotes
1 week
36.12
Extreme 36.12
39.95
1 month
30.95
Extreme 30.95
40.69
Current year
23.58
Extreme 23.58
40.69
1 year
17.53
Extreme 17.53
44.66
3 years
17.53
Extreme 17.53
59.84
5 years
17.53
Extreme 17.53
70.82
10 years
4.03
Extreme 4.03
78.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 19-09-30
Director of Finance/CFO 39 23-07-12
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 79 15-06-14
Chairman 72 01-07-31
Director/Board Member 63 05-11-30
More insiders
Date Price Change Volume
24-06-13 36.78 -2.35% 89 274
24-06-12 37.67 -0.05% 645,832
24-06-11 37.69 +0.21% 588,025
24-06-10 37.61 +2.98% 1,257,965
24-06-07 36.52 -1.11% 548,956

Delayed Quote Nasdaq, June 12, 2024 at 04:00 pm EDT

More quotes
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
37.67 USD
Average target price
36.73 USD
Spread / Average Target
-2.50%
Consensus